FIVE REASONS to Think About Clinical Trials in JAPAN
Why TARGET the Japanese Market?
Japan is the SECOND LARGEST single-nation PHARMECEUTICAL MARKET
The Japanese pharmaceutical market is relatively UNTAPPED by FOREIGN pharmaceutical/biotech COMPANIES
Home to the LARGEST Elderly Population IN THE WORLD
*In developed countries such as Japan and the United States, 34 percent of prescription medication and 30 percent of OTC medication use are by the elderly population. The Japanese elderly population tops all others, those aged 65 or older accounting for 26.7% of its population of 127.11 million people, and continues to grow.
The culture’s MEDICINE-FRIENDLY MINDSET and FULLY DEVELOPED national healthcare coverage
A FAST and AMBITIOUS Regulatory System
*The Clinical Trial Notification (CTN) scheme, different from the IND process, allows for first submission new chemical entities to start clinical trials 30 days after the CTN has been submitted to the PMDA regulatory authority.
*Orphan Drug Development
Need FIVE more?
Why CONDUCT clinical trials in Japan:
CLINICAL DEVELOPMENT Infrastructure and Logistics’ QUALITY, SAFETY, and RELIABILITY levels are HIGH, as well as GLOBALLY COMPETITIVE
TEASILY ACCESS the Japanese Market
EASILY OBTAIN needed Asian data for trials IN YOUR OWN REGION
PROCURE Japanese/ASIAN data for BRIDGING and MULTI-REGIONAL TRIALS
Target OTHER ASIAN Markets; SIMULTANEOUSLY conduct Japanese and Caucasian Trials